Skip to main content
Premium Trial:

Request an Annual Quote

Caprotec Enters Second Collaboration with Bayer CropScience for Use of CCMS Technology

NEW YORK (GenomeWeb News) – Berlin-based biotech-firm Caprotec Bioanalytics said today that it has entered a research collaboration with Bayer CropScience to identify and study an agrochemical target.

The collaboration will use Caprotec's Capture Compound Mass Spectrometry technology to profile the interactions of Bayer CropScience compounds with the proteome of various biological systems. The agreement builds on a previous collaboration between the two companies begun in December 2011 that similarly used the CCMS technology for analysis of a target of interest.

Caprotec's CCMS technology uses capture compounds to reversibly bind target proteins on the basis of small molecule-protein interactions. The captured proteins are then pulled out and analyzed via mass spectrometry.

Financial and other terms of the agreement were not disclosed.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.